Medigene to Present at 2024 Cell and Gene Therapy Summit

Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the "Company"), a firm specializing in immuno-oncology and T cell immunotherapies for solid tumors, is set to give a virtual presentation at the 7th Cell and Gene Therapy In-Depth Focus Summit, which will be held from June 27-28, 2024, in Beijing, China.

The event will be hosted at the Crown Hotel Youtang in Beijing, and Medigene's presentation is scheduled for June 27, 2024, from 4.30 to 5 pm local time. Dr. Kirsty Crame, the Vice President of Clinical Strategy & Development, will deliver the presentation. The title of the talk is "MDG1015: a 3rd Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory Switch Protein, Advancing to the Clinic."

Medigene's presentation will spotlight their leading program, MDG1015. This therapy represents a pioneering third-generation T cell receptor-engineered T cell (TCR-T) therapy. MDG1015 targets NY-ESO-1/LAGE-1a (New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a) and is augmented with the PD1-41BB costimulatory switch protein. The initial human trial for MDG1015 is slated for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma, and synovial sarcoma. The company plans to file for an Investigational New Drug (IND) by the third quarter of 2024 and aims to submit a Clinical Trial Application (CTA) by the fourth quarter of 2024.

About Medigene AG:
Medigene AG (FSE: MDG1) is an immuno-oncology company committed to the development of unique T cell therapies for solid tumor treatments. The company's End-to-End Platform integrates various proprietary and exclusive technologies, which allow the generation of optimal T cell receptors against cancer testis antigens and neoantigens. These receptors are then used to create enhanced TCR-T therapies that are distinguished by their safety, efficacy, and durability. This platform supports not only Medigene's own therapy pipeline but also partnerships with other organizations. Medigene’s lead TCR-T program, MDG1015, is poised for an IND filing in the third quarter of 2024 and a CTA filing in the fourth quarter of the same year.

Medigene® is a registered trademark of Medigene AG and may be owned or licensed in certain regions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!